Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.

Journal of Clinical Microbiology
L R BadenG M Eliopoulos

Abstract

We characterized baseline and repopulating stool isolates recovered during a phase II trial of ramoplanin for the treatment of patients with stool carriage of vancomycin-resistant enterococci (VRE). Repopulation with a strain with a related genotype was found in 74, 60, and 53% of individuals in groups treated with placebo, 100 mg of ramoplanin, and 400 mg of ramoplanin, respectively. All ramoplanin-treated patients with a culture positive for VRE at day 7 had a relapse caused by a genotypically related isolate. In ramoplanin-treated patients, antibiotics with activities against anaerobic organisms were associated with positive cultures on day 7 (relative risk [RR] = 8.8; P = 0.004), and the avoidance of such antibiotics was significantly associated with culture negativity through day 21 (RR = 0.16; P = 0.02).

References

Mar 1, 1992·Journal of Clinical Microbiology·R V Goering, M A Winters
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·P W CaufieldN K Childers
May 1, 1985·The Journal of Antimicrobial Chemotherapy·K P FuE A Konopka
Feb 1, 1994·Diagnostic Microbiology and Infectious Disease·C A O'DonovanR H Eng
Feb 1, 1994·Antimicrobial Agents and Chemotherapy·N MobarakaiD Landman
Jun 1, 1993·Endodontics & Dental Traumatology·P OharaJ D Kettering
Feb 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G G RaoF Ojo
Apr 1, 1996·Journal of Clinical Microbiology·K G van HornK M Rodney
Nov 7, 1996·The New England Journal of Medicine·H S Gold, R C Moellering
Apr 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D W BeezholdR A Weinstein
Aug 1, 1997·Journal of Clinical Microbiology·D F SahmL M Mundy
Sep 7, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M R WeinsteinJ M Conly
Mar 9, 2000·The New England Journal of Medicine·B E Murray
Mar 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A R TenorioR A Weinstein
Jul 20, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K E MondyL M Mundy
Oct 6, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M T WongUNKNOWN Ramoplanin VRE2 Clinival Stury Group
Oct 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L R BadenG M Eliopoulos

❮ Previous
Next ❯

Citations

May 25, 2004·Antimicrobial Agents and Chemotherapy·Usha StiefelCurtis J Donskey
Sep 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Amy J RayCurtis J Donskey
Jan 31, 2003·Expert Opinion on Investigational Drugs·Neil Woodford
Jun 11, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Usha StiefelCurtis J Donskey
Dec 20, 2002·Biopolymers·Dewey G McCaffertyWenkai Li
Jan 11, 2005·Current Opinion in Infectious Diseases·Carlos Torres-Viera, Louise-Marie Dembry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved